Home/Pipeline/MSC-Klotho

MSC-Klotho

Kidney Disease

Pre-clinicalActive

Key Facts

Indication

Kidney Disease

Phase

Pre-clinical

Status

Active

Company

Kyttaro

About Kyttaro

Kyttaro Therapeutics is a private, preclinical-stage biotech leveraging a proprietary platform of genetically modified mesenchymal stem cells (MSCs). With a foundation in 15 years of R&D and a portfolio of 58 patents, the company is advancing programs in Graft vs. Host Disease (GvHD), Type 1 Diabetes, kidney disease, and combination therapies with CAR-T. Headquartered in Munich, Kyttaro is preparing to initiate clinical trials for its lead GvHD program in Europe and the US while seeking partnerships to expand its pipeline.

View full company profile

Therapeutic Areas

Oncology Immunology Metabolic Disease Cardiovascular Nephrology Neurodegenerative Diseases

Other Kidney Disease Drugs

Drug	Company	Phase	Status
NOX4 Inhibitor Platform	Glucox Biotech	Research	Active
Undisclosed	R1 Therapeutics	Pre-clinical	Active
Multimodal Nephrology Care	Medice	Commercial	Active
USP30 Inhibitor Program	Vincere Biosciences	Preclinical	Active